Module 2: Choosing Wisely – Personalizing Therapy in HER2-Mutant NSCLC
Webcast
0.5 Contact Hours OVERVIEW
Module 2: Choosing Wisely – Personalizing Therapy in HER2-Mutant NSCLC is organized by i3 Health.
Statement of Need:
Human epidermal growth factor receptor 2 (HER2) alterations, including gene mutations, gene amplifications, and protein overexpression, represent promising therapeutic targets in non–small cell lung cancer (NSCLC). HER2-targeted therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, are available for HER2-mutant NSCLC, and their indications are expanding to the first-line setting (NCCN, 2026). Due to the complexities of treatment selection, it is crucial to individualize treatment based on disease factors and patient preferences. Module 2 of this Clinical Insights Microlearning Series will explore how to personalize therapy in HER2-mutant NSCLC. It will feature insights from Zofia Piotrowska, MD, MHS, Associate Professor of Medicine at Harvard Medical School and Clinical Co-Director of the MGB Thoracic Medical Oncology Program at Massachusetts General Hospital, with nursing perspectives from Victoria Sherry, DNP, ANP-BC, AOCNP®, and pathology perspectives from Soo-Ryum (Stewart) Yang, MD.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Select the most appropriate treatment approach for patients with HER2-mutant NSCLC based on disease factors and patient preferences
ACCREDITATION & CREDITS
Credits:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development:
A maximum of 0.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.3 contact hours of pharmacology credit for Advanced Practice Registered Nurses.
- Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 0.5 ANCC contact hours.
ONCC RECERTIFICATION:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
- OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, TCTCN®, ROCN®, and BMTCN® renewal candidates may apply 0.5 ILNA points toward:
- Oncology Nursing Practice (OCN®, CPHON®, AOCNP®)
- Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
- Treatment (AOCNP®, CBCN®, CPHON®, OCN®, ROCN®)
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.
TARGET AUDIENCE
OncologistsNursesHealthcare ProvidersNurse PractitionersSPECIALITIES
Oncology
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
Quick Links